Put Your Best Chin Forward
Fullness under your chin can make you look older or heavier than you actually are and oftentimes won’t go away despite exercise and healthy eating. KYBELLA® is a first-of-its-kind injectable treatment for adults with submental fullness (i.e., a double chin) that destroys fat cells to improve your chin profile.
Call us today for a free consultation!
Before & After Photos
Frequently Asked Questions
How does it work?
The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, KYBELLA® destroys fat cells, resulting in a noticeable reduction in fullness under the chin.
How long do the results last?
Once the fat cells are destroyed by KYBELLA, those cells cannot store or accumulate fat. After reaching your desired aesthetic goal, further treatment is not expected. Results will vary in each individual.*
How is it administered?
At each treatment, you will receive multiple small injections under your chin, and the injection process takes about 15 to 20 minutes. The exact number of injections will depend on the amount of fat you have under your chin and your desired profile.
How many treatments will I need?
Since everyone’s chin profile is different, the number of treatments varies from patient to patient. The aesthetic professionals at Sublime will help determine how many treatment sessions you need based on the amount and distribution of your submental fat and your personal treatment goals. Each KYBELLA® treatment session is given at least 1 month apart, and you should not receive more than 6 treatments. In clinical studies, 59% of patients received 6 treatments.
*Results will vary in each individual
KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Important Safety Information
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full Prescribing Information.